8 Analysts Have This to Say About BioNTech
Portfolio Pulse from Benzinga Insights
BioNTech (NASDAQ:BNTX) has received ratings from 8 analysts in the last quarter, with 2 being bullish and 6 indifferent. The average 12-month price target for the company is $131.75, an increase of 2.82% from the previous average of $128.14.
October 17, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioNTech has received mostly indifferent ratings from analysts, with a few bullish. The average 12-month price target has increased, indicating a potential positive short-term impact on the stock.
Analyst ratings can significantly influence stock prices. While the majority of analysts are indifferent about BioNTech, the increase in the average 12-month price target suggests a positive outlook, which could lead to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100